(2023). Identifying subtypes of heart failure from three electronic health record sources with machine learning: an external, prognostic, and genetic validation study. Lancet Digit Health, 5, e370-e379. http://doi.org/10.1016/s2589-7500(23)00065-1
. A. Banerjee
First name
A.
Last name
Banerjee
(2023). Predicting the risk of acute kidney injury in primary care: derivation and validation of STRATIFY-AKI. Br J Gen Pract. http://doi.org/10.3399/bjgp.2022.0389
. (2023). The association between antihypertensive treatment and serious adverse events by age and frailty: A cohort study. Plos Med, 20, e1004223. http://doi.org/10.1371/journal.pmed.1004223
. (2023). Severe COVID-19 outcomes by cardiovascular risk profile in England in 2020: a population-based cohort study. Lancet Reg Health Eur, 27, 100604. http://doi.org/10.1016/j.lanepe.2023.100604
. (2023). Identifying subtypes of chronic kidney disease with machine learning: development, internal validation and prognostic validation using linked electronic health records in 350,067 individuals. Ebiomedicine, 89, 104489. http://doi.org/10.1016/j.ebiom.2023.104489
. (2022). Primary prevention of acute cardiovascular events by influenza vaccination: an observational study. Eur Heart J. http://doi.org/10.1093/eurheartj/ehac737
. (2022). Using national electronic health records for pandemic preparedness: validation of a parsimonious model for predicting excess deaths among those with COVID-19-a data-driven retrospective cohort study. J R Soc Med, 1410768221131897. http://doi.org/10.1177/01410768221131897
. (2022). Development and external validation of a risk prediction model for falls in patients with an indication for antihypertensive treatment: retrospective cohort study. Bmj, 379, e070918. http://doi.org/10.1136/bmj-2022-070918
. (2021). Lower risk of hospitalization for heart failure, kidney disease and death with sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease. Diabetes Obes Metab, 23, 2207-2214. http://doi.org/10.1111/dom.14437
. (2021). Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study. Diabetes Obes Metab, 23, 75-85. http://doi.org/10.1111/dom.14189
.